Edition:
United States

Galapagos NV (GLPG.OQ)

GLPG.OQ on NASDAQ Stock Exchange Global Select Market

115.33USD
16 Feb 2018
Change (% chg)

$-1.40 (-1.20%)
Prev Close
$116.73
Open
$116.42
Day's High
$116.93
Day's Low
$114.81
Volume
25,613
Avg. Vol
36,189
52-wk High
$121.08
52-wk Low
$67.35

Select another date:

Mon, Jan 8 2018

BRIEF-ProQR And Galapagos Announce Research Collaboration

* PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY

BRIEF-Galapagos Reports Preliminary Topline Results In Osteoarthritis Study

* REPORTED ON SUNDAY, POSITIVE PRELIMINARY TOPLINE RESULTS WITH A PHASE 1B STUDY IN OSTEOARTHRITIS (OA) PATIENTS IN THE UNITED STATES

BRIEF-Galapagos Exercises Co-Promotion Option For Filgotinib

* SAID ON THURSDAY IT WILL OPT-IN ON CO-PROMOTION OF FILGOTINIB WITH COLLABORATION PARTNER GILEAD SCIENCES IN EIGHT EUROPEAN COUNTRIES, SHOULD FILGOTINIB BE APPROVED FOR COMMERCIAL SALE

BRIEF-Galapagos To Enter NASDAQ Biotech Index Effective Dec 18‍​

* TO ENTER NASDAQ BIOTECH INDEX EFFECTIVE DEC 18‍​ Source text: http://bit.ly/2jM5AGV Further company coverage: (Gdynia Newsroom)

BRIEF-Galapagos NV ‍announces share capital increase arising from warrant exercises​

* ‍Announces a share capital increase arising from warrant exercises​

BRIEF-Galapagos NV reports Q3 loss of ‍1.75​ euro per share

* Galapagos NV qtrly ‍revenues 106.4 million euro versus 65 million euro​

BRIEF-Galapagos & Morphosys announce Phase 1 results with joint investigational antibody program MOR106

* Co, Morphosys report first promising signs of clinical activity in phase 1 study with IL-17C antibody MOR106 in Atopic Dermatitis patients

Select another date: